The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Significance Statement: Because race and sex affect serum creatinine levels independently of GFR, the Food and Drug Administration’s previous creatinine-based metformin contraindication may have inadvertently caused racial and sex disparities in metformin prescription among patients with diabetes and moderate kidney dysfunction. It is unknown whether these disparities were mitigated after a 2016 labeling change to an eGFR-based contraindication. The authors found that before the labeling change, among patients with eGFR of 30–44 ml/min per 1.73 m 2, Black patients and men were underprescribed metformin for diabetes compared with White patients and women, respectively. Racial and sex disparities were attenuated in patients with eGFR of 30–44 ml/min per 1.73 m 2 after the label change. These results suggest that drug dosing recommendations solely on the basis of serum creatinine may cause racial and sex disparities in its use. Background: In 2016, the Food and Drug Administration (FDA) changed labeling regarding metformin contraindications in patients with diabetes and CKD from using serum creatinine–based thresholds to using eGFR-based thresholds. Because race and sex affect serum creatinine levels independently of GFR, the earlier creatinine-based contraindication may have inadvertently caused racial and sex disparities in metformin prescription among patients with low eGFR. Methods: In an analysis of 15,946 Black and White primary care patients with diabetes and eGFR≥30 ml/min per 1.73 m 2 in a large health system (the primary cohort), we assessed the association of race and sex with metformin prescription across eGFR level before and after the FDA label change. For a replication cohort, we meta-analyzed data from 36 cohorts with 1,051,723 patients from OptumLabs Data Warehouse. Results: In the primary cohort, before the label change, Black patients with eGFR of 30–44 ml/min per 1.73 m 2 were prescribed metformin less often than White counterparts (adjusted prevalence ratio [aPR], 0.65; 95% confidence interval [95% CI], 0.52 to 0.82); this disparity was significantly attenuated after the label change (aPR, 0.90; 95% CI, 0.74 to 1.09; P value for interaction by period =0.04). Results were consistent in the replication cohorts. Men with eGFR of 30–44 ml/min per 1.73 m 2 received metformin prescriptions less often than women counterparts before the label change; this was nonsignificantly attenuated after the label change, but we found significant attenuation in the replication cohorts (aPR pre-label change, 0.76; 95% CI, 0.73 to 0.79; aPR post-label change, 0.85; 95% CI, 0.83 to 0.88; P value for interaction by period <0.001). Conclusions: The metformin label change to an eGFR-based contraindication may have reduced racial and sex disparities in metformin prescription in moderate kidney dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Self-citationGoff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437741.48606.98 · Cited by 3,697
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Predictors of New-Onset Kidney Disease in a Community-Based Population
Fox, C. S. (2004) · JAMA · doi:10.1001/jama.291.7.844 · Cited by 1,241 · cited 1×
“, baseline comparison periods: [1] August 7, 2012 to May 1, 2013; [2] May 2, 2013 to January 24, 2014; [3] January 25, 2014 to October 19, 2014; and [4] October 20, 2014 to July 14, 2015) to compare with the 9-month period prevalent cohort after the label change, and then, we assessed racial and sex differences in met…”
Method9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency
Lipska, K. J., Bailey, C. J., & Inzucchi, S. E. (2011) · Diabetes Care · doi:10.2337/dc10-2361 · Cited by 432
Reconsidering the Consequences of Using Race to Estimate Kidney Function
Eneanya, N. D., Yang, W., & Reese, P. P. (2019) · JAMA · doi:10.1001/jama.2019.5774 · Cited by 385
Diabetes and cause-specific mortality in a prospective cohort of one million U.S. Adults
Campbell, P. T., Newton, C. C., Patel, A. V., Jacobs, E. J., & Gapstur, S. M. (2012) · Diabetes Care · doi:10.2337/dc12-0002 · Cited by 339 · cited 1×
“, baseline comparison periods: [1] August 7, 2012 to May 1, 2013; [2] May 2, 2013 to January 24, 2014; [3] January 25, 2014 to October 19, 2014; and [4] October 20, 2014 to July 14, 2015) to compare with the 9-month period prevalent cohort after the label change, and then, we assessed racial and sex differences in met…”
MethodGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297
Cited by
New creatinine- and cystatin C-based equations to estimate GFR without race
Inker, L. A., Eneanya, N. D., Coresh, J., Tighiouart, H., Wang, D., Sang, Y., Crews, D. C., Doria, A., Estrella, M. M., Froissart, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102953 · Cited by 4,695
Self-citationDelgado, C., Baweja, M., Crews, D. C., Eneanya, N. D., Gadegbeku, C. A., Inker, L. A., Mendu, M. L., Miller, W. G., Moxey-Mims, M. M., Roberts, G. V., et al. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.08.003 · Cited by 783
Self-citationDelgado, C., Baweja, M., Crews, D. C., Eneanya, N. D., Gadegbeku, C. A., Inker, L. A., Mendu, M. L., Miller, W. G., Moxey-Mims, M. M., Roberts, G. V., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021070988 · Cited by 423
Self-citationRace, genetic ancestry, and estimating kidney function in CKD
Hsu, C.-Y., Yang, W., Parikh, R. V., Anderson, A. H., Chen, T. K., Cohen, D. L., He, J., Mohanty, M. J., Lash, J. P., Mills, K. T., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103753 · Cited by 241
Health inequities and the inappropriate use of race in nephrology
Eneanya, N. D., Boulware, L. E., Tsai, J., Bruce, M. A., Ford, C. L., Harris, C., Morales, L. S., Ryan, M. J., Reese, P. P., Thorpe, R. J., et al. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00501-8 · Cited by 140
Metadata
- Authors
- Shin, J.-I., Sang, Y., Chang, A. R., Dunning, S. C., Coresh, J., Inker, L. A., Selvin, E., Ballew, S. H., & Grams, M. E.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2020-07-13
- Volume
- 31
- Issue
- 8
- Pages
- 1847-1858
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- OpenAlex
- W3042894330
- Cited by
- 38
- References
- 12
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD. https://app.cochat.ai/papers/10.1681/asn.2019101119
- The paper
- Shin, J.-I., Sang, Y., Chang, A. R., Dunning, S. C., Coresh, J., Inker, L. A., Selvin, E., Ballew, S. H., & Grams, M. E. (2020). The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2019101119
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.